Completed PHASE2 INTERVENTIONAL 2-arm NCT00574223

A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

Double-Blind, Placebo-Controlled Study to Investigate Safety, Tolerability, Immunogenicity and Clinical Efficacy of a Specific Immunotherapy Combining Allergen With CYT003-QbG10 (CYT005-AllQbG10) in Adult Patients With Perennial Allergic Rhinoconjunctivitis Due to House Dust Mite Allergy

Sponsor: Cytos Biotechnology AG

Conditions House Dust Mite Allergy Perennial Allergic Rhinoconjunctivitis

Interventions CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10) House dust mite allergen extract in combination with CYT003-QbG10-placebo

Updated 5 times since 2017 Last updated: Apr 24, 2009 Started: Nov 30, 2007 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00574223, this PHASE2 trial focuses on House Dust Mite Allergy and Perennial Allergic Rhinoconjunctivitis and remains completed. Sponsored by Cytos Biotechnology AG, it has been updated 5 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cytos Biotechnology AG

Data source: Cytos Biotechnology AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Schlieren, Switzerland